Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML)
The purpose of this study is to evaluate treatment patterns and associated outcomes for CP-CML patients who fail Imatinib 400 mg daily in a real-world setting.
Chronic Myeloid Leukemia
Complete Cytogenic Response (CCyR) for CP-CML patients who failed Imatinib 400 mg daily, At 3 months post treatment change|Complete Cytogenic Response (CCyR) for CP-CML patients who failed Imatinib 400 mg daily, At 6 months post treatment change|Complete Cytogenic Response (CCyR) for CP-CML patients who failed Imatinib 400 mg daily, At 12 months post treatment change
Prognostic factors (clinical and demographic characteristics) that influence treatment selection for CP-CML patients who fail imatinib 400 mg daily, Baseline|Prognostic factors (clinical and demographic characteristics) that influence treatment selection for CP-CML patients who fail imatinib 400 mg daily, 3 months after start of treatment|Prognostic factors (clinical and demographic characteristics) that influence treatment selection for CP-CML patients who fail imatinib 400 mg daily, 6 months after start of treatment|Prognostic factors (clinical and demographic characteristics) that influence treatment selection for CP-CML patients who fail imatinib 400 mg daily, 12 months after start of treatment|Best response rates achieved by patients if no CCyR, Baseline|Best response rates achieved by patients if no CCyR, 3 months after start of treatment|Best response rates achieved by patients if no CCyR, 6 months after start of treatment|Best response rates achieved by patients if no CCyR, 12 months after start of treatment
Time Perspective: Retrospective and Prospective